Sarah E. Haecker
Sarah A. Haecker, PhD
Advisor, Regenerative Medicine Business
Formerly a Director with CTG, Dr. Sarah Haecker was recently recruited by Orasi Medical, Inc. to be their Vice President of Pharmaceutical Business Development. Sarah remains as an Advisor to Cell Therapy Group and its clients in regenerative medicine.
Prior to joining CTG and then Orasi,
Sarah
was an independent business strategist in the Regenerative Medicine
Industry. With more than 16 years of senior-level management experience
she uniquely combines technical and business knowledge with emphasis in
strategy, business development, licensing, opportunity assessment,
market analysis and partnering early to late stage technologies in the
private and public sectors.
Her client list encompasses big pharma to emerging ReGEN and stem cell based companies, investment banking and venture to academia. She has both published and spoken to a world-wide audience in the area of progressive, innovative stem cell science and specifically on business modeling in the ReGEN Industry.
With postdoctoral training in the School of Medicine and Gene Therapy Program at the University of Pennsylvania, Sarah has a broad technical knowledge base in regenerative medicine, tissue engineering, stem cell biology and application, gene and cell therapy, translational research, and clinic applications.
Dr. Haecker has authored numerous articles in both the scientific as well as the business literature. She holds a doctorate degree in molecular biology and bioethics from the University of Minnesota and a bachelor of science degree in biochemistry from the University of Wisconsin. She has continued education in the MBA program at the University of Pennsylvania’s Wharton School.
__________________________________________________________________________________________
Advisor, Regenerative Medicine Business
Formerly a Director with CTG, Dr. Sarah Haecker was recently recruited by Orasi Medical, Inc. to be their Vice President of Pharmaceutical Business Development. Sarah remains as an Advisor to Cell Therapy Group and its clients in regenerative medicine.
Prior to joining CTG and then Orasi,
Sarah
was an independent business strategist in the Regenerative Medicine
Industry. With more than 16 years of senior-level management experience
she uniquely combines technical and business knowledge with emphasis in
strategy, business development, licensing, opportunity assessment,
market analysis and partnering early to late stage technologies in the
private and public sectors. Her client list encompasses big pharma to emerging ReGEN and stem cell based companies, investment banking and venture to academia. She has both published and spoken to a world-wide audience in the area of progressive, innovative stem cell science and specifically on business modeling in the ReGEN Industry.
With postdoctoral training in the School of Medicine and Gene Therapy Program at the University of Pennsylvania, Sarah has a broad technical knowledge base in regenerative medicine, tissue engineering, stem cell biology and application, gene and cell therapy, translational research, and clinic applications.
Dr. Haecker has authored numerous articles in both the scientific as well as the business literature. She holds a doctorate degree in molecular biology and bioethics from the University of Minnesota and a bachelor of science degree in biochemistry from the University of Wisconsin. She has continued education in the MBA program at the University of Pennsylvania’s Wharton School.
__________________________________________________________________________________________